FDA slaps a clinical hold on Solid Bio’s gene therapy for Duchenne MD in wake of safety alert — shares tank – Endpoints News
Endpoints News |
FDA slaps a clinical hold on Solid Bio's gene therapy for Duchenne MD in wake of safety alert — shares tank
Endpoints News Just a few weeks after Solid Biosciences $SLDB put out an 11th hour notice that its gene therapy for Duchenne muscular dystrophy had been put on a partial clinical hold due to safety concerns, just ahead of its $125 million IPO, the biotech is back … |
